Causes of death and re‐hospitalization in cardiogenic shock

References

• Goldberg R. J., Samad N. A., Yarzebski J., Gurwitz J., Bigelow C., Gore J. M. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340: 1162–8
   PubMed Web of Science ®Google Scholar
• Califf R. M., Bengtson J. R. Cardiogenic shock. N Engl J Med 1994; 330: 1724–30
   PubMed Web of Science ®Google Scholar
• Hasdai D., Topol E. J., Califf R. M., Berger P. B., Holmes D. R., Jr. Cardiogenic shock complicating acute coronary syndromes. Lancet 2000; 356: 749–56
   PubMedGoogle Scholar
• Hochman J. S., Sleeper L. A., White H. D., Dzavik V., Wong S. C., Menon V., et al. One‐year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190–2
   PubMed Web of Science ®Google Scholar
• Hochman J. S., Sleeper L. A., Webb J. G., Sanborn T. A., White H. D., Talley J. D., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?. N Engl J Med 1999; 341: 625–34
   PubMed Web of Science ®Google Scholar
• Cotter G., Kaluski E., Blatt A., Milovanov O., Moshkovitz Y., Zaidenstein R., et al. L‐NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000; 101: 1358–61
   PubMed Web of Science ®Google Scholar
• Cotter G., Kaluski E., Milo O., Blatt A., Salah A., Hendler A., et al. LINCS: L‐NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003; 24: 1287–95
   PubMed Web of Science ®Google Scholar
• Hochman J. S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107: 2998–3002
   PubMed Web of Science ®Google Scholar
• Li H., Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 190: 244–54
   PubMed Web of Science ®Google Scholar
• Liuzzo G., Buffon A., Biasucci L. M., Gallimore J. R., Caligiuri G., Vitelli A., et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98: 2370–6
   PubMed Web of Science ®Google Scholar
• Neumann F. J., Ott I., Gawaz M., Richardt G., Holzapfel H., Jochum M., et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92: 748–55
   PubMed Web of Science ®Google Scholar
• Buffon A., Biasucci L. M., Liuzzo G., D'Onofrio G., Crea F., Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5–12
   PubMed Web of Science ®Google Scholar
• Haverkate F., Thompson S. G., Pyke S. D., Gallimore J. R., Pepys M. B. Production of C‐reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462–6
   PubMed Web of Science ®Google Scholar
• Liuzzo G., Biasucci L. M., Gallimore J. R., Grillo R. L., Rebuzzi A. G., Pepys M. B., et al. The prognostic value of C‐reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417–24
   PubMed Web of Science ®Google Scholar
• Hollenberg S. M., Kavinsky C. J., Parrillo J. E. Cardiogenic shock. Ann Intern Med 1999; 131: 47–59
   PubMed Web of Science ®Google Scholar
• Hochman J. S., Sleeper L. A., Godfrey E., McKinlay S. M., Sanborn T., Col J., et al. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK: an international randomized trial of emergency PTCA/CABG‐trial design. Am Heart J 1999; 137: 313–21
   Google Scholar
• Levy M. M., Fink M. P., Marshall J. C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 1999; 31: 1250–6
   Google Scholar
• Kohsaka S., Menon V., Lowe A. M., Lange M., Dzavik V., Sleeper L. A., et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005; 165: 1643–50
   PubMed Web of Science ®Google Scholar
• Lim N., Dubois M. J., De Backer D., Vincent J. L. Do all nonsurvivors of cardiogenic shock die with a low cardiac index?. Chest 2003; 124: 1885–91
   Google Scholar
• Valencia R., Theroux P., Granger C. B., Mahaffey K. W., Gudaye T., Malloy K., et al. Congestive heart failure and cardiogenic shock complicating acute myocardial infarction have high mortality and are associated with intense inflammatory response: results from the CARDINAL trials (abstract). J Am Coll Cardiol 2004; 43: A291
   Google Scholar
• Geppert A., Steiner A., Zorn G., Delle‐Karth G., Koreny M., Haumer M., et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin‐6. Crit Care Med 2002; 30: 1987–94
   Google Scholar
• Dzavik V., Cotter G., Farkouh M. E., Ramanathan K., Reynolds H. R., Baran D., et al. Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with acute myocardial infarction complicated by cardiogenic shock: a phase 2 dose ranging study (abstract). Circulation 2004; 110
   Google Scholar
• Granger C. B., Mahaffey K. W., Weaver W. D., Theroux P., Hochman J. S., Filloon T. G., et al. Pexelizumab, an anti‐C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184–90
   PubMed Web of Science ®Google Scholar
• Menon V. Cardiogenic shock: have we really found the magic potion?. Eur Heart J 2003; 24: 1279–81
   Google Scholar
• Theroux P., Armstrong P. W., Mahaffey K. W., Hochman J. S., Malloy K. J., Rollins S., et al. Prognostic significance of blood markers of inflammation in patients with ST‐segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005; 26: 1964–70
   PubMed Web of Science ®Google Scholar
• Solomon S. D., Zelenkofske S., McMurray J. J., Finn P. V., Velazquez E., Ertl G., et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581–8
   PubMed Web of Science ®Google Scholar
• Hohnloser S. H., Kuck K. H., Dorian P., Roberts R. S., Hampton J. R., Hatala R., et al. Prophylactic use of an implantable cardioverter‐defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481–8
   PubMed Web of Science ®Google Scholar
• Wilber D. J., Zareba W., Hall W. J., Brown M. W., Lin A. C., Andrews M. L., et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004; 109: 1082–4
   PubMedGoogle Scholar
• Bardy G. H., Lee K. L., Mark D. B., Poole J. E., Packer D. L., Boineau R., et al. Amiodarone or an implantable cardioverter‐defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225–37
   PubMed Web of Science ®Google Scholar
• Pitt B., White H., Nicolau J., Martinez F., Gheorghiade M., Aschermann M., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46: 425–31
   PubMed Web of Science ®Google Scholar
• Tortolani A. J., Risucci D. A., Rosati R. J., Dixon R. In‐hospital cardiopulmonary resuscitation: patient, arrest and resuscitation factors associated with survival. Resuscitation 1990; 20: 115–28
   Google Scholar
• Tunstall‐Pedoe H., Bailey L., Chamberlain D. A., Marsden A. K., Ward M. E., Zideman D. A. Survey of 3765 cardiopulmonary resuscitations in British hospitals (the BRESUS Study): methods and overall results. BMJ 1992; 304: 1347–51
   Google Scholar
• Epstein A. E., Powell J., Yao Q., Ocampo C., Lancaster S., Rosenberg Y., et al. In‐hospital versus out‐of‐hospital presentation of life‐threatening ventricular arrhythmias predicts survival: results from the AVID Registry. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol 1999; 34: 1111–6
   Google Scholar
• Gwinnutt C. L., Columb M., Harris R. Outcome after cardiac arrest in adults in UK hospitals: effect of the 1997 guidelines. Resuscitation 2000; 47: 125–35
   Google Scholar
• Thiele H., Sick P., Boudriot E., Diederich K. W., Hambrecht R., Niebauer J., et al. Randomized comparison of intra‐aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005; 26: 1276–83
   PubMed Web of Science ®Google Scholar
• Keenan S. P., Dodek P., Chan K., Hogg R. S., Craib K. J., Anis A. H., et al. Intensive care unit admission has minimal impact on long‐term mortality. Crit Care Med 2002; 30: 501–7
   Google Scholar
• Keenan S. P., Dodek P., Chan K., Simon M., Hogg R. S., Anis A. H., et al. Intensive care unit survivors have fewer hospital readmissions and readmission days than other hospitalized patients in British Columbia. Crit Care Med 2004; 32: 391–8
   PubMed Web of Science ®Google Scholar
• Desideri A., Fioretti P. M., Cortigiani L., Gregori D., Coletta C., Vigna C., et al. Cost of strategies after myocardial infarction (COSTAMI): a multicentre, international, randomized trial for cost‐effective discharge after uncomplicated myocardial infarction. Eur Heart J 2003; 24: 1630–9
   PubMed Web of Science ®Google Scholar